UNSPSC 51293801: Pirolazamide

This classification denotes an antidepressant agent with the molecular formula C23H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GQN5BVM24W, chemically known as pyrrolo(1,2-a)pyrazine-2(1h)-butanamide, hexahydro-alpha,alpha-diphenyl- but generally known as pirolazamide, which bears US NIH Compound Identifier 71442. European Medicines Agency schedules Pirolazamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09933MIG.

UNSPSC 51293801 Pirolazamide is a Commodity code that nominally designates a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not align with that narrow scope. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are pirolazamide. State and local procurement systems appear to be using this code as a catch-all for pharmaceutical and health-related product procurement rather than for the specific chemical compound the code nominally represents. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both direct government procurement and cooperative purchasing vehicles designed to serve multiple jurisdictions simultaneously.

Recent activity concentrates in Florida, Texas, and Minnesota, though MMCAP's cooperative model extends to participating states including Oregon. Seminole County, Florida released an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program focused on bypassing traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration's MMCAP issued an RFP (Solicitation Number S1070000015802) on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with awarded vendors effective July 1, 2026. The code shows active but misaligned procurement activity; vendors should verify that pirolazamide-specific opportunities exist before investing in pursuit under this designation.